CVS Health (CVS) Price Target Cut to $80.00

CVS Health (NYSE:CVS) had its price target dropped by Robert W. Baird from $85.00 to $80.00 in a research note issued on Friday. The firm presently has a “neutral” rating on the pharmacy operator’s stock. Robert W. Baird’s price objective indicates a potential upside of 15.29% from the stock’s current price.

Other equities analysts also recently issued reports about the company. Needham & Company LLC downgraded CVS Health from a “strong-buy” rating to a “buy” rating and dropped their price target for the stock from $100.00 to $98.00 in a research note on Friday. ValuEngine downgraded CVS Health from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Mizuho set a $90.00 price target on CVS Health and gave the stock a “buy” rating in a research note on Tuesday, October 24th. Leerink Swann raised their price target on CVS Health from $82.00 to $90.00 and gave the stock an “outperform” rating in a research note on Monday, January 8th. Finally, Vetr cut CVS Health from a “hold” rating to a “sell” rating and set a $76.66 target price on the stock. in a report on Tuesday, January 16th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $87.77.

CVS Health (NYSE CVS) traded down $1.16 during mid-day trading on Friday, hitting $69.39. The stock had a trading volume of 16,717,348 shares, compared to its average volume of 8,720,000. The stock has a market cap of $70,290.00, a P/E ratio of 11.76, a P/E/G ratio of 1.24 and a beta of 0.92. CVS Health has a 52-week low of $66.45 and a 52-week high of $84.00. The company has a current ratio of 1.05, a quick ratio of 0.55 and a debt-to-equity ratio of 0.67.

CVS Health (NYSE:CVS) last released its quarterly earnings results on Thursday, February 8th. The pharmacy operator reported $1.92 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.88 by $0.04. The firm had revenue of $48.39 billion for the quarter, compared to the consensus estimate of $47.54 billion. CVS Health had a return on equity of 16.96% and a net margin of 2.77%. The company’s revenue for the quarter was up 5.3% on a year-over-year basis. During the same period last year, the business posted $1.71 EPS. sell-side analysts expect that CVS Health will post 5.88 earnings per share for the current year.

In other CVS Health news, EVP Lisa Bisaccia sold 29,445 shares of the firm’s stock in a transaction dated Thursday, December 21st. The stock was sold at an average price of $75.00, for a total transaction of $2,208,375.00. Following the sale, the executive vice president now directly owns 15,556 shares of the company’s stock, valued at $1,166,700. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 0.61% of the stock is currently owned by company insiders.

A number of large investors have recently bought and sold shares of the business. Jackson Grant Investment Advisers Inc. raised its holdings in CVS Health by 0.6% during the second quarter. Jackson Grant Investment Advisers Inc. now owns 2,881 shares of the pharmacy operator’s stock valued at $232,000 after acquiring an additional 18 shares during the period. Traynor Capital Management Inc. raised its holdings in CVS Health by 1.3% during the second quarter. Traynor Capital Management Inc. now owns 3,676 shares of the pharmacy operator’s stock valued at $290,000 after acquiring an additional 48 shares during the period. Sequoia Financial Advisors LLC raised its holdings in CVS Health by 0.8% during the second quarter. Sequoia Financial Advisors LLC now owns 6,406 shares of the pharmacy operator’s stock valued at $515,000 after acquiring an additional 53 shares during the period. Brookstone Capital Management raised its holdings in CVS Health by 1.8% during the second quarter. Brookstone Capital Management now owns 3,153 shares of the pharmacy operator’s stock valued at $254,000 after acquiring an additional 55 shares during the period. Finally, Mengis Capital Management Inc. raised its holdings in CVS Health by 0.7% during the second quarter. Mengis Capital Management Inc. now owns 11,415 shares of the pharmacy operator’s stock valued at $918,000 after acquiring an additional 75 shares during the period. 81.69% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: “CVS Health (CVS) Price Target Cut to $80.00” was reported by American Banking News and is owned by of American Banking News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/09/cvs-health-cvs-price-target-cut-to-80-00.html.

About CVS Health

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Analyst Recommendations for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply